Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

BACKGROUND: Inhibitors targeting immune checkpoint were proved effective in cancer immunotherapy, such as PD-1/PD-L1 blockade. The novel immune checkpoint TIGIT/PVR plays critical roles in suppressing the anti-tumor effects of CD8(+) T and NK cells, and dual blockade of TIGIT/PVR and PD-1/PD-L1 by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiuman, Du, Jiangfeng, Wang, Hongfei, Chen, Chunxia, Jiao, Ling, Cheng, Xiangrui, Zhou, Xiaowen, Chen, Shaomeng, Gou, Shanshan, Zhao, Wenshan, Zhai, Wenjie, Chen, Junhui, Gao, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487564/
https://www.ncbi.nlm.nih.gov/pubmed/32894141
http://dx.doi.org/10.1186/s12964-020-00638-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487564/
https://www.ncbi.nlm.nih.gov/pubmed/32894141
http://dx.doi.org/10.1186/s12964-020-00638-2

Ejemplares similares